The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab

ConclusionIn order to stratify the risk for developing ICH before the initiation of bevacizumab, we recommend to assess for the presence of cerebral macrobleeding as it is associated with ICH development.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research